A detailed history of Albion Financial Group transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Albion Financial Group holds 225 shares of FATE stock, worth $753. This represents 0.0% of its overall portfolio holdings.

Number of Shares
225
Previous 225 -0.0%
Holding current value
$753
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022

BUY
$47.84 - $64.34 $1,674 - $2,251
35 Added 18.42%
225 $13,000
Q2 2021

Aug 12, 2021

BUY
$67.25 - $92.52 $3,362 - $4,626
50 Added 35.71%
190 $16,000
Q4 2020

Feb 19, 2021

BUY
$38.09 - $100.95 $5,332 - $14,133
140 New
140 $13,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $325M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Albion Financial Group Portfolio

Follow Albion Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Albion Financial Group , based on Form 13F filings with the SEC.

News

Stay updated on Albion Financial Group with notifications on news.